|
Group (field collaboration)
|
Vaccines (type)
|
Target
|
|
Apovia, USA; New York University, USA
|
ICC-1132 (protein)
|
Pre-erythrocytic
|
|
GlazoSmithKline Biologicals, Belgium; and WRAIR, USA (Medical Research Council [MRC] Laboratories, The Gambia; Centro de investigacao em Suade de Manhica [CISM], Mozambique)
|
RTS,S (protein)
|
Pre-erythrocytic
|
|
Malaria Vaccine Development Unit, National Institutes of Health, USA
|
Pvs25, AMA-1 (protein)
|
Transmission blocking, blood stage
|
|
Naval Medical Research Center (NMRC), USA; Vical USA
|
Pf-CS, Pf-SSP2/TRAP, Pf-LSA-1, Pf-EXP-1, Pf-LSA-3 (DNA vaccines)
|
Pre-erythrocytic
|
|
New York University, USA
|
CS (synthetic polymers, MAPs, polyoximes)
|
Pre-erythrocytic
|
|
Oxford University, UK (MRC Laboratories, The Gambia; Wellcome-Kenya Medical MVA Research Institute [KEMRI] collaboration, Kilifi, Kenya)
|
DNA ME-TRAP, ME-TRAP, FP9 ME-TRAP, MVA-CS (DNA and recombinant viral)
|
Pre-erythrocytic
|
|
Statens Serum Institut (SSI), Copenhagen; Institut Pasteur; Institute of Lausanne, Switzerland
|
GLURP, MSP-3 (synthetic peptide)
|
Pre-erythrocytic, blood stage
|
|
Walter and Eliza Hall Institute of Medical Research, Melbourne; Queensland Institute of Medical Research (QIMR), Brisbane; Swiss Tropical Institute; Biotech Australia Pty (Papua New Guinea Institute of Medical Research)
|
MSP-1, MSP-2, RESA (protein)
|
Blood stage
|
|
Walter Reed Army Institute of Research (WRAIR), USA (KEMRI, Kisumu, Kenya)
|
FMP-1 (protein)
|
Blood stage
|
|
EXP = exported protein. LSA = liver stage antigen. MAP = multiple antigen peptide. Pvs = Plasmodium vivax surface protein. AMA-1 = apical membrane antigen-1. RESA = ring infected erythrocyte surface antigen. SSP2 and TRAP are synonyms: sporozoite surface protein 2 and thrombospondin-related adhesion protein.
Only vaccines being tested in clinical trials as of May 2003 are listed. Field collaborations are listed only if field trials of the candidate had begun as of May 2003.
SOURCE: Moorthy et al. (2004).
|
Items in cart [0]
